Wrightson raid hints at biotech 'super-company'

Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.

It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.

The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.

Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.

British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Fonterra announces Mainland Group leadership change
OCA - Oceania announces Director changes as part of Board refresh
AIA - Analyst and media webcast for FY26 interim results
The Warehouse Group confirms leaner operating structure
SML - Synlait provides half year performance update
RYM - Refreshed strategy and new capital management framework
ENS - Clarification of Gina Tuzcet’s status
BGP - 4th Quarter Sales to 25 January 2026
Contact Energy 2026 Half Year Results Presentation
February 2nd Morning Report